Navigation Links
Brain Scans Using New Dye May Predict Alzheimer's
Date:7/11/2012

WEDNESDAY, July 11 (HealthDay News) -- Brain scans using a new radioactive dye can detect early evidence of Alzheimer's disease in people who show little or no signs of the disease and may help predict future mental decline, a new study says.

It included 151 people who completed thinking and memory tests and underwent a PET (positron emission tomography) brain scan with the new dye called florbetapir (Amyvid). They were then followed for three years.

The dye binds to amyloid plaques that occur in the brains of people with Alzheimer's disease, enabling doctors to see if patients have the plaques and how much.

At the start of the study, 69 patients had normal mental function, 51 had mild impairment and 31 had Alzheimer's disease.

After 18 months, thinking and memory test results of patients who started off with mild impairment and whose brain scans revealed evidence of amyloid plaques worsened to a greater degree than those who had mild impairment but had no evidence of plaques at the start of the study.

The patients with amyloid plaques at the outset were also more likely to go on to develop Alzheimer's. After three years, 29 percent of the plaque-positive patients with mild impairment developed Alzheimer's compared with 10 percent of those with mild impairment who had no plaques at the start of the study.

Among participants with normal mental function at the start of the study, those with evidence of brain plaques showed more mental decline after 18 months than those with no sign of plaques.

"Even at a short follow-up of 18 months we can see how the presence of amyloid plaques affects cognitive [thinking] function," study co-leader Dr. P. Murali Doraiswamy, a professor of psychiatry at Duke University, said in a university news release. "Most people who come to the doctor with mild impairment really want to know the short-term prognosis and potential long-term effect."

There is no cure for Alzheimer's, but being able to detect the early stages of Alzheimer's could help advance efforts to find ways to fight the disease and enhance the care and treatment of current patients, he explained.

"For the most part we have been blind about who would progress and who wouldn't, so this approach is a step toward having a biomarker that predicts risk of decline in people who are experiencing cognitive impairment," Doraiswamy said.

The study, published online July 11 in the journal Neurology, was funded by Eli Lilly/Avid Radiopharmaceuticals, which markets Amyvid. Doraiswamy receives advisory and speaker fees from Lilly/Avid.

According to the U.S. Food and Drug Administration, Amyvid was approved in April for use in imaging tests for patients being evaluated for Alzheimer's.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Alzheimer's disease.

-- Robert Preidt

SOURCE: Duke University, news release, July 11, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Epilepsy Leads to More Brain Abnormalities Over Time
3. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
4. Why is traumatic brain injury increasing among the elderly?
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Dental X-Rays May Be Linked to Benign Brain Tumors
7. Nonsurgical Method to Measure Brain Pressure Shows Promise
8. Researchers Map Brain Regions Linked to Intelligence
9. Football-related catastrophic brain injuries on the rise
10. Brain Tumor Vaccine Shows Promise in Early Trial
11. Brain Surgery Might Ease Tough-to-Treat OCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The ... range of cosmetic services. , “We’re excited to add this excellent dermatology practice ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 ... the freedom of recovery, they often feel shame for having struggled with an eating ... (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- to ...
(Date:1/20/2017)... ... , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, ... on wheels, it can be wheeled out of the way and stored when not in ... "We have transformed the feedback from customers into specific enhancements and created a new product ...
(Date:1/20/2017)... ... 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted ... world. Yisrayl says this generation is a time like no other and society needs to ... , Yisrayl says he does not want to sound like an old bible beater because ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a ... the January ECRM trade show to continue the marketing and distribution of its product, ... known for providing 400 percent better absorption than traditional vitamin C supplements. At the ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
(Date:1/19/2017)... 19, 2017 New Review ... Address Motor Symptoms and Motor Complications in Mid- ... ... (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... global  pacemaker market  is expected to reach USD 12.3 billion by 2025, according ... cardiac conditions coupled with the availability of medical coverage is a key driving ... devices are supporting the expansion of this vertical. ... ... Logo ...
Breaking Medicine Technology: